Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

69.63 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
An Overview of Exact Sciences's Earnings
 
Via Benzinga
Exact Sciences (EXAS) To Report Earnings Tomorrow: Here Is What To Expect
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close. Here’s what to expect. 
Via StockStory
Topics World Trade
Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test
From Exact Sciences Corp.
Via Business Wire
3 Cash-Producing Stocks We Find Risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
Thermo Fisher, Exact Sciences, Integer Holdings, Revvity, and 10x Genomics Shares Are Falling, What You Need To Know
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like... 
Via StockStory
Topics Lawsuit World Trade
Exact Sciences Schedules Second Quarter 2025 Earnings Call
From Exact Sciences Corp.
Via Business Wire
1 Healthcare Stock for Long-Term Investors and 2 to Be Wary Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer
From Exact Sciences Corp.
Via Business Wire
Forecasting The Future: 9 Analyst Projections For Exact Sciences
 
Via Benzinga
Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out
BofA analysts review the promise and limits of AI in precision medicine, highlighting key players like Tempus, Guardant, and Exact Sciences. 
Via Benzinga
Topics Artificial Intelligence
1 of Wall Street’s Favorite Stock with Promising Prospects and 2 to Turn Down
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Topics Economy
A Look Back at Immuno-Oncology Stocks’ Q1 Earnings: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Pack
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
3 Mid-Cap Stocks in the Doghouse
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap
From Exact Sciences Corp.
Via Business Wire
Exact Sciences to Participate in June Investor Conference
From Exact Sciences Corp.
Via Business Wire
3 Low-Volatility Stocks Walking a Fine Line
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025
From Exact Sciences Corp.
Via Business Wire
EXAS Q1 Earnings Call: Outperformance Driven by Commercial Execution, New Products, and Margin Expansion
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q1 CY2025, with sales up 10.9% year on year to $706.8 million. The company’s full-year revenue... 
Via StockStory
1 Healthcare Stock Worth Investigating and 2 to Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years
Via The Motley Fool
Exact Sciences Earns 2025 Great Place To Work® Certification™
From Exact Sciences Corp.
Via Business Wire
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performing large-cap stocks in the last week: DUOL, CRWV, THC, CARR, SMMT, AUR, ANET, TT, DXCM, XPO. Most had positive financial results and raised guidance. 
Via Benzinga
Exact Sciences (EXAS) Stock Trades Up, Here Is Why
Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) jumped 15.2% in the morning session after the company reported strong first quarter 2025 results which beat analysts' revenue and... 
Via StockStory
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance
Exact Sciences posted better-than-expected Q1 results and lifted its 2025 outlook, signaling confidence in growth and operational momentum. 
Via Benzinga
Exact Sciences to Participate in May Investor Conference
From Exact Sciences Corp.
Via Business Wire
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Exact Sciences (NASDAQ:EXAS) Posts Better-Than-Expected Sales In Q1, Stock Soars
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 10.9% year on year to $706.8 million. The company’s full-year revenue... 
Via StockStory
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Exact Sciences Hikes Its Full-Year Outlook. But There's One First-Quarter Drawback.
The company hiked its sales guidance for the year, but reported steeper-than-expected first-quarter losses. 
Via Investor's Business Daily
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.